ALEC · Alector, Inc. · Executive Compensation
Market Cap
$238.95M
Shares
111.66M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Arnon Rosenthal | Co-founder, Chief Executive Officer | $1,995,018 |
| Dr. Sara Kenkare-Mitra | Former President and Head of Research and Development | $1,575,150 |
| Neil Berkley | Chief Financial Officer and Chief Business Officer | $1,052,459 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Arnon Rosenthal | Co-founder, Chief Executive Officer | $3,666,341 |
| Dr. Sara Kenkare-Mitra | President and Head of Research and Development | $2,549,681 |
| Neil Berkley | Chief Financial Officer and Chief Business Officer | $2,289,826 |
| Marc Grasso | Chief Financial Officer | $1,687,869 |
| Gary Romano | M.D., Ph.D. Chief Medical Officer | $1,564,142 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Arnon Rosenthal | Co-founder, Chief Executive Officer | $4,255,007 |
| Dr. Sara Kenkare-Mitra | President and Head of Research and Development | $2,606,214 |
| Marc Grasso | Chief Financial Officer | $1,715,846 |
| Gary Romano | M.D., Ph.D. Chief Medical Officer | $1,618,921 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Sara Kenkare-Mitra | President and Head of Research and Development | $8,870,409 |
| Marc Grasso | Chief Financial Officer | $6,011,780 |
| Gary Romano | M.D., Ph.D. Chief Medical Officer | $3,905,899 |
| Arnon Rosenthal | Co-founder, Chief Executive Officer | $3,515,398 |
| Robert King | Former Chief Development Officer | $692,718 |
| Linda Rubinstein | — | $116,400 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Arnon Rosenthal | Co-founder, Chief Executive Officer | $9,612,580 |
| Shehnaaz Suliman | Former President and Chief Operating Officer | $3,290,757 |
| Robert King | Former Chief Development Officer | $1,924,198 |
| Calvin Yu | Vice President, Finance | $1,375,653 |
| Robert Paul | M.D., Ph.D. | $1,126,315 |
| Dr. Sara Kenkare-Mitra | President and Head of Research and Development | $526,841 |
| Linda Rubinstein | — | $306,150 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Shehnaaz Suliman | Former President and Chief Operating Officer | $8,345,136 |
| Arnon Rosenthal | Co-founder, Chief Executive Officer, and Director | $3,662,229 |
| Robert King | Former Chief Development Officer | $1,392,178 |
| Robert Paul | M.D., Ph.D. Chief Medical Officer | $1,311,587 |
| Former ChiefMedicalOfficer | — | $1,311,587 |
| Calvin Yu | Vice President, Finance | $828,326 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Arnon Rosenthal | Co-founder, Chief Executive Officer, and Director | $6,854,338 |
| Robert Paul | M.D., Ph.D. Chief Medical Officer | $2,307,855 |
| Former ChiefMedicalOfficer | — | $2,307,855 |
| Robert King | Chief Development Officer | $2,257,877 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Arnon Rosenthal | Co-founder, Chief Executive Officer, and Director | $5,453,983 |
| Robert Paul | M.D., Ph.D. Chief Medical Officer | $3,216,095 |
| Robert King | Chief Development Officer | $2,072,775 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Neil Berkley | Chief Financial Officer | Appointed | 2025-12-12 |
| Sara Kenkare-Mitra, Ph.D. | President and Head of Research and Development | Resigned | 2025-10-21 |
| Grace Wong-Sarad | Vice President, Accounting | Appointed | 2025-06-13 |
| Neil Berkley | Interim Chief Financial Officer | Appointed | 2025-06-13 |
| Marc Grasso | Chief Financial Officer | Resigned | 2025-06-13 |
| Dr. Gary Romano | Chief Medical Officer | Resigned | 2025-03-28 |
Key facts
CIK
1653087
CUSIP
014442107
13F (30d)
60 filings
60 filers
Visit website
Investor relations